Tethys picks up $25M for diabetes diagnostic
Tethys Bioscience, maker of a diagnostic test that indicates which patients are at the highest risk for developing Type 2 diabetes, has raised $25 million in a fourth round of funding. Based in Emeryville, Calif., the company is backed by Aeris Capital, Wasatch Advisors, Intel Capital, Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures. It has raised about $80 million to date.
Next Story: Trinity Biosystems raises $7.5M bridge to treat endocrine disorders
Previous Story: Metabolex takes $8.6M to treat diabetes
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.